Reactive oxygen species-mediated therapeutic control of bladder cancer

Nature Reviews Urology

Volumn 8, Issue 11, 2011, Pages 608-616

  Wang, Hwa Chain R ^a   Choudhary, Shambhunath ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ALPHA INTERFERON; ARSENIC TRIOXIDE; BCG VACCINE; BELINOSTAT; BUTHIONINE SULFOXIMINE; CISPLATIN; DIETHYLMALEATE; DOVITINIB; DOXORUBICIN; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; GLUTATHIONE; GREEN TEA EXTRACT; HISTONE DEACETYLASE INHIBITOR; IMMUNOSTIMULATING AGENT; MALEIC ACID DERIVATIVE; METHOTREXATE; OLMESARTAN; ORANTINIB; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VINBLASTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CELL DEATH; CELL LEVEL; CELL SPECIFICITY; CLINICAL TRIAL (TOPIC); CYSTECTOMY; DRUG TARGETING; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 81055147509     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.135     Document Type: Review

References (107)

1. American Cancer Society. Cancer Facts & Figures 2006 [online], http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2006 (2011).
2. American Cancer Society. Cancer Facts & Figures 2007 [online], http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2007 (2011).
3. American Cancer Society. Cancer Facts & Figures 2008 [online], http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2008 (2011).
4. American Cancer Society. Cancer Facts & Figures 2009 [online], http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2009 (2011).
5. American Cancer Society. Cancer Facts & Figures 2010 [online], http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-and-figures-2010 (2011).
6. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003). (Pubitemid 38041357)
7. Reuter, V. E. The pathology of bladder cancer. Urology 67 (3 Suppl. 1), 11-17 (2006).
8. Sexton, W. J. et al. Bladder cancer: a review of non-muscle invasive disease. Cancer Control 17, 256-268 (2010).
9. Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. & Cordon-Cardo, C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol. 28, 401-408 (2010).
10. Goebell, P. J. & Knowles, M. A. Bladder cancer or bladder cancers Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28, 409-428 (2010).
11. Wu, X. R. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 5, 713-725 (2005).
12. Williamson, S. R. et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit. Rev. Oncol. Hematol. 76, 112-126 (2010).
13. Choudhary, S. & Wang, H. C. Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol. Cancer Ther. 6, 1099-1111 (2007). (Pubitemid 46554581)
14. Macaluso, M., Montanari, M., Cinti, C. & Giordano, A. Modulation of cell cycle components by epigenetic and genetic events. Semin. Oncol. 32, 452-457 (2005). (Pubitemid 41396421)
15. Wu, Z & Yu, Q. E2F1-mediated apoptosis as a target of cancer therapy. Curr. Mol. Pharmacol. 2, 149-160 (2009).
16. Tomlinson, D. C., Baldo, O., Harnden, P. & Knowles, M. A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91-98 (2007). (Pubitemid 47354570)
17. Hart, K. C. et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19, 3309-3320 (2000). (Pubitemid 30487417)
18. Kanai, M., Go¨ke, M., Tsunekawa, S. & Podolsky, D. K. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J. Biol. Chem. 272, 6621-6628 (1997). (Pubitemid 27118147)
19. McCubrey, J. A. et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta. 1773, 1263-1284 (2007). (Pubitemid 47125967)
20. Leicht, D. T. et al. Raf kinases: function, regulation and role in human cancer. Biochim. Biophys. Acta. 1773, 1196-1212 (2007). (Pubitemid 47161035)
21. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J. & Der, C. J. Increasing complexity of Ras signaling. Oncogene 17, 1395-1413 (1998). (Pubitemid 28458409)
22. Jebar, A. H. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24, 5218-5225 (2005). (Pubitemid 41192438)
23. Cheng, J. et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 62, 4157-4163 (2002). (Pubitemid 34791088)
24. López-Knowles, E. et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66, 7401-7404 (2006). (Pubitemid 44289191)
25. Choudhary, S., Rathore, K. & Wang, H. C. Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells. J. Cancer Res. Clin. Oncol. 137, 471-480 (2011).
26. 2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death. Mol. Carcinog. 50, 215-219 (2011).
27. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach Nat. Rev. Drug Discov. 8, 579-591 (2009).
28. Kamata, T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci. 100, 1382-1388 (2009).
29. Pervaiz, S. & Clement, M. V. Superoxide anion: oncogenic reactive oxygen species Int. J. Biochem. Cell. Biol. 39, 1297-1304 (2007). (Pubitemid 47031046)
30. Kim, E. Y. et al. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic. Biol. Med. 49, 1072-1081 (2010).
31. Yoo, M. H., Song, H., Woo, C. H., Kim, H. & Kim, J. H. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation. Oncogene 23, 9259-9268 (2004). (Pubitemid 40069696)
32. Shimada, K. et al. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res. 69, 3157-3164 (2009).
33. Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017-2019 (2000). (Pubitemid 30158678)
34. Dasgupta, S., Hoque, M. O., Upadhyay, S. & Sidransky, D. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res. 68, 700-706 (2008). (Pubitemid 351206745)
35. Hempel, N., Ye, H., Abessi, B., Mian, B. & Melendez, J. A. Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic. Biol. Med. 46, 42-50 (2009).
36. Cho, H. J. et al. Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J. Biol. Chem. 277, 19358-19366 (2002).
37. Yang, J. Q., Li, S., Domann, F. E., Buettner, G. R. & Oberley, L. W. Superoxide generation in v-Ha-ras-transduced human keratinocyte HaCaT cells. Mol. Carcinog. 26, 180-188 (1999). (Pubitemid 29529569)
38. Santillo, M. et al. Opposing functions of Ki-and Ha-Ras genes in the regulation of redox signals. Curr. Biol. 11, 614-619 (2001). (Pubitemid 32324765)
39. Liu, R., Li, B. & Qiu, M. Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha. Oncogene 20, 1486-1496 (2001). (Pubitemid 32291199)
40. Mitsushita, J., Lambeth, J. D. & Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res. 64, 3580-3585 (2004). (Pubitemid 38657935)
41. Shinohara, M. et al. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J. Biol. Chem. 282, 17640-17648 (2007). (Pubitemid 47100324)
42. Choudhary, S. & Wang, H. C. Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J. Cancer Res. Clin. Oncol. 135, 1601-1613 (2009).
43. Choudhary, S., Rathore, K. & Wang, H. C. FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death. Anticancer Drugs 21, 831-840 (2010).
44. Adachi, Y. et al. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27, 4921-4932 (2008).
45. Matés, J. M., Segura, J. A., Alonso, F. J. & Márquez, J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch. Toxicol. 82, 273-299 (2008).
46. Ushio-Fukai, M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 11, 1289-1299 (2009).
47. Pan, J. S., Hong, M. Z. & Ren, J. L. Reactive oxygen species: a double-edged sword in oncogenesis. World J. Gastroenterol. 15, 1702-1707 (2009).
48. Verschoor, M. L., Wilson, L. A. & Singh, G. Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can. J. Physiol. Pharmacol. 88, 204-219 (2010).
49. Spadaro, D. et al. The redox switch: dynamic regulation of protein function by cysteine modifications. Physiol. Plant 138, 360-371 (2010).
50. Meng, T. C., Fukada, T. & Tonks, N. K. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell 9, 387-399 (2002). (Pubitemid 34195563)
51. 2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl Acad. Sci. USA 105, 7147-7152 (2008). (Pubitemid 351754446)
52. 2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase. Microvasc. Res. 69, 36-44 (2005). (Pubitemid 40410466)
53. 2 regulates the activation of distinct MAPK pathways. Free Radic. Biol. Med. 33, 1121-1132 (2002).
54. Liu, L. Z. et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 41, 1521-1533 (2006).
55. Tabet, F. et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ. Res. 103, 149-158 (2008).
56. Wang, J. F., Zhang, X. & Groopman, J, E. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 279, 27088-27097 (2004). (Pubitemid 38812545)
57. Zhang, P., Wang, Y. Z., Kagan, E. & Bonner, J. C. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J. Biol. Chem. 275, 22479-22486 (2000). (Pubitemid 30621836)
58. Kim, H. S., Song, M. C., Kwak, I. H., Park, T. J. & Lim, I, K. Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J. Biol. Chem. 278, 37497-37510 (2003). (Pubitemid 37175271)
59. Levinthal, D. J. & Defranco, D. B. Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons. J. Biol. Chem. 280, 5875-5883 (2005). (Pubitemid 40280070)
60. Kamata, H. et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661 (2005). (Pubitemid 40343077)
61. Giannoni, E., Taddei, M. L. & Chiarugi, P. Src redox regulation: again in the front line. Free Radic. Biol. Med. 49, 516-527 (2010).
62. Hoyos, B. et al. Activation of c-Raf kinase by ultraviolet light. Regulation by retinoids. J. Biol. Chem. 277, 23949-23957 (2002). (Pubitemid 34952240)
63. Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J. & Stein, J. P. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev. Urol. 10, 31-43 (2008).
64. Heney, N. M. et al. Superficial bladder cancer: progression and recurrence. J. Urol. 130, 1083-1086 (1983). (Pubitemid 14207227)
65. Oosterlinck, W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol. Nefrol. 56, 65-72 (2004). (Pubitemid 38937540)
66. Lamm, D. L., Riggs, D. R., Traynelis, C. L. & Nseyo, U. O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 153, 1444-1450 (1995).
67. Gontero, P. et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur. Urol. 46, 339-343 (2004). (Pubitemid 39078568)
68. Serretta, V., Galuffo, A., Pavone, C., Allegro, R. & Pavone-MacAluso, M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology 65, 65-69 (2005). (Pubitemid 40169607)
69. Sylvester, R. J., van der Meijden, A. P. & Lamm, D. L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964-1970 (2002).
70. Witjes, J. A. Management of BCG failures in superficial bladder cancer: a review. Eur. Urol. 49, 790-797 (2006).
71. Chiong, E. & Esuvaranathan, K. New therapies for non-muscle-invasive bladder cancer. World J. Urol. 28, 71-78 (2010).
72. Huang, G. J. & Stein, J. P. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr. Opin. Urol. 17, 369-375 (2007). (Pubitemid 47344626)
73. Sternberg, C. N. et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139, 461-469 (1988). (Pubitemid 18082866)
74. Roberts, J. T. et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/ cisplatin in patients with locally advanced and metastatic bladder cancer. Ann. Oncol. 17 (Suppl. 5), v118-v122 (2006). (Pubitemid 43985220)
75. Sternberg, C. N. et al. Seven year update of an EORTC phase III trial of high-dose intensity MVAC chemotherapy and G-CSF vs. classic MVAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006). (Pubitemid 41814532)
76. Pliarchopoulou, K., Laschos, K. & Pectasides, D. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol. Oncol. doi:10.1016/j.urolonc.2010.07.011
77. Pollard, C., Smith, S. C. & Theodorescu, D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev. Mol. Med. 12, e10 (2010).
78. Bellmunt, J., Hussain, M. & Dinney, C. P. Novel approaches with target therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit. Rev. Oncol. Hematol. 46 (Suppl.), S85-S104 (2003). (Pubitemid 36808975)
79. Duggan, B. J. et al. The role of antisense oligonucleotides in the treatment of bladder cancer. Urol. Res. 30, 137-147 (2002). (Pubitemid 36056658)
80. Cappellen, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999).
81. Martindale, J. L. & Holbrook, N. J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192, 1-15 (2002). (Pubitemid 34587382)
82. Antico Arciuch, V. G., Alippe, Y., Carreras, M. C. & Poderoso, J. J. Mitochondrial kinases in cell signaling: Facts and perspectives. Adv. Drug Deliv. Rev. 61, 1234-1249 (2009).
83. Acharya, A., Das, I., Chandhok, D. & Saha, T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev. 3, 23-34 (2010).
84. Marks, P. A., Miller, T. & Richon, V. M. Histone deacetylases. Curr. Opin. Pharmacol. 3, 344-351 (2003). (Pubitemid 36908937)
85. Espino, P. S., Drobic, B., Dunn, K. L. & Davie, J. R. Histone modifications as a platform for cancer therapy. J. Cell. Biochem. 94, 1088-1102 (2005). (Pubitemid 41420232)
86. Dokmanovic, M. & Marks, P. A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96, 293-304 (2005). (Pubitemid 41437862)
87. Ueda, H. et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47, 301-310 (1994). (Pubitemid 24106520)
88. Ueda, H. et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 47, 315-323 (1994). (Pubitemid 24106522)
89. Vigushin, D. M. FR-901228 Fujisawa/National Cancer Institute. Curr. Opin. Investig. Drugs 3, 1396-1402 (2002).
90. Wagner, J. M., Hackanson, B., Ludie;bbert, M. & Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 1, 117-136 (2010).
91. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921 (2002). (Pubitemid 34984414)
92. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006). (Pubitemid 44348499)
93. Karam, J. A. et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int. J. Cancer 120, 1795-1802 (2007). (Pubitemid 46399368)
94. Choudhary, S. & Wang, H. C. Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitors to induce apoptosis of human cancer HT29 cells. J. Cancer Res. Clin. Oncol. 133, 725-739 (2007). (Pubitemid 47319239)
95. Fecteau, K. A., Mei, J. & Wang, H. C. Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. J. Pharmacol. Exp. Ther. 300, 890-899 (2002). (Pubitemid 34164993)
96. Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673-678 (2005). (Pubitemid 40282724)
97. Buckley, M. T. et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J. Transl. Med. 5, 49 (2007).
98. Estrela, J. M., Ortega, A. & Obrador, E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43, 143-181 (2006). (Pubitemid 43860449)
99. Awasthi, Y. C. et al. Physiological and pharmacological significance of glutathione-conjugate transport. J. Toxicol. Environ. Health B Crit. Rev. 12, 540-551 (2009).
100. Pompella, A., Corti, A., Paolicchi, A., Giommarelli, C. & Zunino, F. Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr. Opin. Pharmacol. 7, 360-366 (2007). (Pubitemid 47289260)
101. Ruzza, P., Rosato, A., Rossi, C. R., Floreani, M. & Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med. Chem. 9, 763-777 (2009).
102. Sau, A., Pellizzari Tregno, F., Valentino, F., Federici, G. & Caccuri, A. M. Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 500, 116-122 (2010).
103. Yang, X. & Flaig, T. W. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int. Braz. J. Urol. 36, 273-282 (2010).
104. Miyajima, A. et al. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer 76, 206-210 (1997). (Pubitemid 27279660)
105. Tanaka, N. et al. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol. Cancer Ther. 9, 2982-2992 (2010).
106. Maeda, H. et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 11, 737-746 (2004). (Pubitemid 39023120)
107. Coyle, C. H., Philips, B. J., Morrisroe, S. N., Chancellor, M. B. & Yoshimura, N. Antioxidant effects of green tea and its polyphenols on bladder cells. Life Sci. 83, 12-18 (2008).